Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness
When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s not just public perception. The science over the last six years has grown by leaps and bounds, as well. Epidiolex, a pharmaceutical-grade CBD oil, went through clinical trials and is being prescribed for thousands of patients with seizures. The founder of GW Pharmaceuticals, the maker of Epidiolex, told me they are now developing cannabis medications for everything from autism to anxiety.
Stories you may be interested in
Are You Prepared For Questions About Medical Cannabis?
With over 85% of Americans supporting legalizing medical cannabis, it’s inevitable that patients will begin asking their primary care doctors about its use and overall efficacy. Doctors and other medical professionals will be called upon to be ‘sense-makers’ for a treatment they never studied in medical school and have limited available research to draw upon. …
Read More 
Data Migration and Mapping Functions
Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions. In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and…
Read More 
Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools
A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More 
New Features
As Arfinn Med has become the leading Electronic Medical Record (EMR) and practice management solution for medical cannabis clinics, we have continued to release new features to help improve clinical workflows and patient care. Our newest feature is a custom intake form builder to help gather pertinent patient information prior to appointments. INTAKE FORM BUILDER…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
CEO Spotlight: James West
As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More